Best Approved Antidepressant for Generalized Anxiety Disorder
Duloxetine is the best approved antidepressant for generalized anxiety disorder, as it is the only SNRI with FDA approval specifically for GAD in both adults and children/adolescents (ages 7 and older), demonstrating consistent efficacy with a favorable tolerability profile. 1
Primary Recommendation
Start with duloxetine 30 mg once daily for one week, then increase to 60 mg once daily. 2 This dosing strategy reduces the most common adverse effect (nausea) while achieving therapeutic benefit. The 60 mg once-daily dose appears as effective as 60 mg twice daily, making adherence easier.
Alternative First-Line Options
If duloxetine is contraindicated or not tolerated, consider these FDA-approved alternatives in order:
SSRIs (FDA-approved for GAD):
- Paroxetine: Most extensively studied SSRI for GAD and the first SSRI approved by the FDA for this indication 3, 4, 5
- Escitalopram: Has the least effect on CYP450 enzymes, reducing drug-drug interaction risk 1
- Sertraline: Effective with moderate tolerability 6
Other SNRIs:
- Venlafaxine extended-release: Demonstrated long-term efficacy (150-225 mg/d), though requires 2-4 weeks to titrate to effective dose 2, 4, 7
Key Clinical Considerations
Efficacy: Antidepressants achieve a 50% reduction in Hamilton Anxiety Rating Scale scores with a number needed to treat of 7 (95% CI 5-9) 8. This represents high-certainty evidence of benefit over placebo.
Tolerability Trade-offs:
- Fewer patients discontinue antidepressants due to lack of efficacy (NNTB = 27) compared to placebo 8
- More patients discontinue due to adverse effects (NNTH = 17) compared to placebo 8
- Overall acceptability is equivalent to placebo 8
Duloxetine-Specific Advantages
- Dual indication: Treats both GAD and commonly comorbid depression 2, 4, 5
- Simple dosing: Once-daily administration improves adherence
- Cardiovascular safety: Does not produce clinically important ECG changes or blood pressure alterations 2
- No routine monitoring required: Aminotransferase monitoring is unnecessary 2
Critical Safety Warnings
For duloxetine specifically:
- Discontinue immediately if jaundice, hepatomegaly, or elevated transaminases develop 1
- Stop at first sign of blisters, peeling rash, mucosal erosions, or Stevens-Johnson syndrome 1
For all antidepressants in GAD:
- Monitor for suicidal thinking/behavior, especially in patients under age 25 1
- Watch for behavioral activation, agitation, or hypomania 1
- Screen for serotonin syndrome when combining with other serotonergic agents 1
Venlafaxine Cautions
If choosing venlafaxine over duloxetine:
- Prescribe with caution in cardiac disease (cardiac conduction abnormalities reported) 2
- Monitor blood pressure (increases can occur) 2
- Must taper when discontinuing to avoid withdrawal syndrome 2
Treatment Duration
Continue antidepressant treatment for 9-12 months after recovery to prevent relapse 9. GAD is a chronic condition requiring long-term management 4, 5, 7.
What NOT to Use First-Line
Avoid benzodiazepines for initial or long-term treatment despite their rapid onset 9, 10. They lack antidepressant properties needed for comorbid depression, cause dependence, and are associated with higher mortality 10.
Monitoring Response
Reassess symptoms at 4-6 weeks. If inadequate response after 6-8 weeks at target dose, consider switching to an alternative first-line antidepressant rather than adding medications 2. The goal is remission, not just symptom reduction.